Clinical Trial Update: Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing low molecular weight heparin (LMWH) to rivaroxaban in Chinese patients hospitalized with acute coronary syndrome evaluates safety and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction
• Myocardial Ischemia
• Unstable Angina

Drugs mentioned

• LMWH (low molecular weight heparin)
• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Second Xiangya Hospital of Central South University | Conditions: Acute Coronary Syndrome, Myocardial Infarction | Phase 4 | Status: COMPLETED